Overview

Donafenib Plus Sintilimab for Advanced HCC

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of donafenib combined with sintilimab in patients with advanced hepatocellullar carcinoma (HCC).
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University